Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Share:
Related ABT
Wide Moat ETF Is On A Tear
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Abbott Laboratories After St. Jude Medical - Good Or Bad? (Seeking Alpha)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

DateFirmActionFromTo
Apr 2016Piper JaffrayDowngradesOverweightNeutral
Mar 2016JefferiesMaintainsBuy
Feb 2016Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!